Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-25 @ 9:45 PM
Study NCT ID:
NCT00314951
Status:
COMPLETED
Last Update Posted:
2017-04-21
First Post:
2006-04-13
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
Sponsor:
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05-02
Start Date Type:
ACTUAL
Primary Completion Date:
2008-07-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-08-21
Completion Date Type:
ACTUAL
First Submit Date:
2006-04-13
First Submit QC Date:
None
Study First Post Date:
2006-04-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-07-01
Results First Submit QC Date:
None
Results First Post Date:
2011-10-26
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2010-08-31
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2017-03-23
Last Update Post Date:
2017-04-21
Last Update Post Date Type:
ACTUAL